Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study

Brad H Rovin; Rainer Boxhammer; Anjali Thakur; Pierre M Ronco

doi:10.1016/j.ekir.2022.05.031

Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study

Kidney Int Rep. 2022 Sep;7(9):2086-2090. doi: 10.1016/j.ekir.2022.05.031. Epub 2022 Jun 10.

Authors

Brad H Rovin¹, Rainer Boxhammer², Anjali Thakur², Pierre M Ronco^{3

4}

Affiliations

¹ The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
² MorphoSys AG, Planegg, Germany.
³ Sorbonne Université/INSERM UMRS 1155, Paris, France.
⁴ Centre Hospitalier du Mans, Le Mans, France.

No abstract available

Keywords: COVID-19 vaccination; anti-CD38 antibody; anti-SARS-CoV-2 antibody response; felzartamab (MOR202/TJ202); membranous nephropathy; plasma cell depletion.